2024-05-21 23:20:45 ET
Summary
- Trulieve reported a 4% increase in total revenue to $298 million for Q1 2024 and a significant rise in gross margin to 58%.
- The Florida Supreme Court approved a ballot measure for the November 2024 election to legalize recreational cannabis, potentially increasing Trulieve's annual revenue by $600 million if passed.
- The DEA's announcement to reschedule cannabis to Schedule III could remove the burdensome 280E tax, significantly impacting Trulieve's financial position and its ongoing tax dispute with the IRS.
- Trulieve appears undervalued compared to its peers, with a forward revenue multiple of 1.87 and EBITDA multiple of 7.75, indicating strong growth potential and a solid capital structure.
- With continued growth and strategic investments, Trulieve is on track to surpass Curaleaf and become the largest U.S. multi-state operator by revenue in 2025, especially if Florida legalizes adult-use cannabis.
Since my previous analysis of Trulieve Cannabis Corp ("Trulieve") (TCNNF) ((CSE:TRUL)), while Trulieve's 2024 Q1 financial results were released, several other historical events also took place.
These historical events are:
- On April 2, 2024 , the Florida Supreme Court approved the ballot measure to legalize recreational cannabis in November 2024 if this ballot gets over 60% vote
- On April 30, 2024 , the news that the United States Drug Enforcement Administration ("DEA") will reschedule cannabis to Schedule III was announced, which was later confirmed by the DEA.
Read the full article on Seeking Alpha
For further details see:
Trulieve's Growth Trajectory: Q1 Success, Florida Legalization Hopes, And DEA Rescheduling Impact